Cellular Membranes and Eicosanoid Synthesis Pathways

The cellular membranes and eicosanoid synthesis pathways represent a complex network of biochemical reactions that convert polyunsaturated fatty acids, primarily arachidonic acid, into potent lipid mediators known as eicosanoids. The process begins when physical or chemical stimuli activate Phospholipase A2 (PLA2), which releases arachidonic acid from the phospholipid bilayer of cellular membranes (StatPearls, 2023). Once liberated, arachidonic acid is metabolized via three primary enzymatic routes: the cyclooxygenase (COX) pathway leading to prostaglandins and thromboxanes, the lipoxygenase (LOX) pathway leading to leukotrienes and lipoxins, and the cytochrome P450 (CYP) pathway leading to epoxyeicosatrienoic acids (EETs) (Nature Reviews Drug Discovery, 2014). These mediators play critical roles in physiological processes such as inflammation, fever, blood pressure regulation, and platelet aggregation. Dysregulation of these pathways is a hallmark of numerous inflammatory and cardiovascular diseases, making the constituent enzymes (like COX-2) and receptors (like CysLT1) major targets for pharmacological intervention (Pharmacological Reviews, 2011). Common therapeutic agents include nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX enzymes, and leukotriene modifiers used in asthma management.

Other names

Arachidonic acid cascadeEicosanoid biosynthetic pathwayArachidonate metabolismProstanoid and leukotriene synthesis pathways

Drugs typically target specific enzymes within the pathway, such as inhibiting Cyclooxygenase (COX-1/2) to prevent prostaglandin synthesis, inhibiting 5-Lipoxygenase (5-LOX) to block leukotriene production, or antagonizing downstream eicosanoid receptors (e.g., CysLT1). Corticosteroids act upstream by inducing lipocortins which inhibit Phospholipase A2 (PLA2), preventing the release of arachidonic acid from cellular membranes.